Nothing Special   »   [go: up one dir, main page]

CL2018001146A1 - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer

Info

Publication number
CL2018001146A1
CL2018001146A1 CL2018001146A CL2018001146A CL2018001146A1 CL 2018001146 A1 CL2018001146 A1 CL 2018001146A1 CL 2018001146 A CL2018001146 A CL 2018001146A CL 2018001146 A CL2018001146 A CL 2018001146A CL 2018001146 A1 CL2018001146 A1 CL 2018001146A1
Authority
CL
Chile
Prior art keywords
compounds
salts
quinolin
imidazo
refers
Prior art date
Application number
CL2018001146A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Thomas Anthony Hunt
Andrew John Eatherton
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2018001146A1 publication Critical patent/CL2018001146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA MEMORIA DESCRIPTIVA SE REFIERE EN GENERAL A COMPUESTOS DE FÓRMULA (I), Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE X, R1, R2, R3, R4 Y R5 TIENEN CUALQUIERA DE LOS SIGNIFICADOS DEFINIDOS EN EL PRESENTE DOCUMENTO. LA MEMORIA DESCRIPTIVA TAMBIÉN SE REFIERE AL USO DE COMPUESTOS DE FÓRMULA (I) Y SALES DE ESTOS PARA TRATAR O PREVENIR UNA ENFERMEDAD MEDIADA POR ATM, INCLUIDO EL CÁNCER. ESTA MEMORIA DESCRIPTIVA SE REFIERE ADEMÁS A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE TIPO IMIDAZO[4,5-C]QUINOLIN-2-ONA SUSTITUIDOS Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS; KITS QUE COMPRENDEN TALES COMPUESTOS Y SALES; MÉTODOS DE PRODUCCIÓN DE TALES COMPUESTOS Y SALES; E INTERMEDIOS ÚTILES EN TAL PRODUCCIÓN.
CL2018001146A 2015-11-03 2018-04-30 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer CL2018001146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CL2018001146A1 true CL2018001146A1 (es) 2018-09-04

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001146A CL2018001146A1 (es) 2015-11-03 2018-04-30 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer

Country Status (20)

Country Link
US (1) US20180318287A1 (es)
EP (1) EP3371183A1 (es)
JP (1) JP2018536649A (es)
KR (1) KR20180070703A (es)
CN (1) CN108349971A (es)
AU (1) AU2016348546B2 (es)
BR (1) BR112018007772A2 (es)
CA (1) CA3002608A1 (es)
CL (1) CL2018001146A1 (es)
CO (1) CO2018003969A2 (es)
CR (1) CR20180307A (es)
GB (1) GB201519406D0 (es)
HK (2) HK1255598A1 (es)
IL (1) IL258818A (es)
MX (1) MX2018005445A (es)
PE (1) PE20181345A1 (es)
PH (1) PH12018500958A1 (es)
RU (1) RU2018120318A (es)
SV (1) SV2018005663A (es)
WO (1) WO2017076895A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP3849984B1 (en) 2018-09-14 2024-11-13 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
JP6997358B2 (ja) * 2018-09-30 2022-01-17 メッドシャイン ディスカバリー インコーポレイテッド キノリノピロリジン－２－オン系誘導化合物及びその使用
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN114746421A (zh) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
ES2974742T3 (es) * 2020-09-21 2024-07-01 Wei Zhong Compuestos de 1-(3,3-difluoropiperidin-4-il)-imidazo[4,5-c]quinolin-2-ona sustituidos con capacidad de penetración en la barrera hematoencefálica
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
WO2023143282A1 (zh) * 2022-01-26 2023-08-03 正大天晴药业集团股份有限公司 含有肼基的化合物
WO2023200427A1 (en) * 2022-04-11 2023-10-19 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative crystal form, salt crystal form, preparation method and application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139747A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
US10457677B2 (en) * 2015-04-02 2019-10-29 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as ATM kinase inhibitors

Also Published As

Publication number Publication date
PE20181345A1 (es) 2018-08-22
RU2018120318A (ru) 2019-12-05
MX2018005445A (es) 2018-08-14
KR20180070703A (ko) 2018-06-26
HK1255598A1 (zh) 2019-08-23
CR20180307A (es) 2018-10-05
EP3371183A1 (en) 2018-09-12
IL258818A (en) 2018-06-28
WO2017076895A1 (en) 2017-05-11
RU2018120318A3 (es) 2019-12-24
BR112018007772A2 (pt) 2018-10-30
CN108349971A (zh) 2018-07-31
US20180318287A1 (en) 2018-11-08
CA3002608A1 (en) 2017-05-11
GB201519406D0 (en) 2015-12-16
SV2018005663A (es) 2018-07-20
AU2016348546B2 (en) 2019-05-02
AU2016348546A1 (en) 2018-06-14
CO2018003969A2 (es) 2018-07-10
JP2018536649A (ja) 2018-12-13
HK1257678A1 (zh) 2019-10-25
PH12018500958A1 (en) 2018-11-19

Similar Documents

Publication Publication Date Title
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2019002527A1 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer.
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer